An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A small medical company called Vivani Medical says it plans to start a human trial as soon as August to test an implant that slowly releases semaglutide, after reaching a deal with Novo Nordisk. The announcement is about timing and a business arrangement, not a finished product. It’s news that the company is moving from lab work toward trying the device in people. Semaglutide is the drug many people have heard of because it’s the active ingredient in weight-loss and diabetes medicines like Ozempic and Wegovy. In plain terms, semaglutide acts like a natural hormone your gut makes that helps you feel full and controls blood sugar. The idea behind an implant is to give a steady, long-lasting dose without needing weekly injections or daily pills. The company’s statement is that they’re aiming to start a human trial in August and that they struck a deal with Novo Nordisk, which is the big company that makes semaglutide. The report doesn’t give full details about how many people will be in the study, exactly how long the implant would release the drug, or what outcomes they will measure. So right now the claim is mainly about plans and partnerships rather than proof that the implant is safe or works in people. This could matter because if an implant reliably delivers semaglutide, it might make treatment easier for people who struggle with regular injections or who want a longer-lasting option. For patients with obesity or type 2 diabetes, a steady-release device could improve convenience and possibly adherence (sticking with treatment). Investors and other medical-device developers will also watch to see whether this approach is feasible and commercially viable. There are important caveats. Early-stage human trials are focused on safety and basic feasibility, not on proving long-term benefit. Implants carry their own risks like infection where they’re placed, device failure, or complications if removal is needed. Semaglutide itself has known side effects such as nausea and digestive issues, and it’s not suitable for everyone (for example, people with certain pancreatic or thyroid conditions may need to avoid it). The report doesn’t say regulatory agencies have approved this implant; it’s only an upcoming trial. Bottom line: Vivani plans to test a semaglutide-releasing implant in people soon, backed by a deal with the drug’s maker, but this is an early step focused on safety and feasibility rather than proof that the device will work or be widely available.
Source: MarketBeat